Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BMYMP - A New Look At CytoDyn's Severe-To-Critical COVID-19 Trial

BMYMP - A New Look At CytoDyn's Severe-To-Critical COVID-19 Trial

Bristol-Myers Squibb $2Pr
  • Trial data is supportive of an EUA: Leronlimab outperformed every approved or recommended drug in critically ill patients.
  • Shorts have a flawed analysis that doesn’t correct for patient age distribution.
  • The clinical outcome of length of hospitalization was statistically significant (p=.005).
  • Dexamethasone is recommended as a standard of care based on age-adjusted meta-analysis data.

For further details see:

A New Look At CytoDyn's Severe-To-Critical COVID-19 Trial
Stock Information
Company Name: Bristol-Myers Squibb $2Pr
Stock Symbol: BMYMP
Market: OTC
Website: bms.com
Menu
BMYMP BMYMP Quote BMYMP Short BMYMP News BMYMP Articles BMYMP Message Board
Get BMYMP Alerts

News, Short Squeeze, Breakout and More Instantly...